Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo

Heart

Volumn 87, Issue 1, 2002, Pages 48-53

  Newby, D E ^a   Witherow, F N ^a   Wright, R A ^a   Bloomfield, P ^a   Ludlam, C A ^b   Boon, N A ^a   Fox, K A A ^a   Webb, D J ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; NITROPRUSSIDE SODIUM; PRAVASTATIN; SUBSTANCE P; TISSUE PLASMINOGEN ACTIVATOR; VASODILATOR AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYSIS; FOREARM BLOOD FLOW; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASODILATATION;

EID: 0036145154     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.87.1.48     Document Type: Article

References (41)

1. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans
2. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia
3. Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolemia extends beyond the muscarinic receptor
4. Coronary risk factors and plaque morphology in men with coronary artery disease who died suddenly
5. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
6. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication
7. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
8. Acute exercise and markers of endothelial injury in peripheral arterial disease
9. Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment
10. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
11. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
12. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels
13. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator
14. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards
15. Prevalence of total coronary artery occlusion during the early hours of transmural myocardial infarction
16. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease
17. Plasminogen-activator inhibitor type 1 and coronary artery disease
18. Gene polymorphism associated with vascular release of tissue-type plasminogen activator (t-PA) in viva
19. Endothelial dysfunction, impaired endogenous fibrinolysis and cigarette smoking: A mechanism for arterial thrombosis and myocardial infarction
20. An in vivo model for the assessment of the acute fibrinolytic capacity of the endothelium
21. The Larginine:nitric oxide pathway contributes to the acute release of tissue plasminogen activator in viva in man
22. The pharmacology of human blood vessels in vivo
23. An evaluation of semi-automatic blood pressure manometers against intra-arterial blood pressure
24. Leiden fibrinolysis working party: Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-I)
25. Sandwich ELISA for t-PA antigen employing a manoclonal antibody
26. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay
27. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma
28. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
29. Statistical methods for assessing agreement between two methods of clinical measurement
30. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction
31. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the thrombolysis in myocardial infarction (TIMI) trial, phase II
32. How do smokers differ from nonsmokers in their response to thrombolysis?
33. Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction: A multivariate analysis
34. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
35. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
36. The effect of pravastalin on coronary events after myocardial infarction in patients with average cholesterol levels
37. Statins do more than just lower cholesterol
38. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women
39. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans
40. Haemostatic variables, incident coronary heart disease and effects of pravastatin: The west of Scotland coronary prevention study
41. Intra-arterial substance P mediated vasodilatation in the human forearm: Pharmacology, reproducibility and tolerability